Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.04
DGX's Cash to Debt is ranked lower than
58% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. DGX: 0.04 )
DGX' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.04

Equity to Asset 0.42
DGX's Equity to Asset is ranked higher than
58% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. DGX: 0.42 )
DGX' s 10-Year Equity to Asset Range
Min: 0.3   Max: 0.62
Current: 0.42

0.3
0.62
Interest Coverage 9.10
DGX's Interest Coverage is ranked higher than
50% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. DGX: 9.10 )
DGX' s 10-Year Interest Coverage Range
Min: 1.82   Max: 17.57
Current: 9.1

1.82
17.57
F-Score: 6
Z-Score: 2.95
M-Score: -2.46
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 19.87
DGX's Operating margin (%) is ranked higher than
95% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. DGX: 19.87 )
DGX' s 10-Year Operating margin (%) Range
Min: -37.2   Max: 20.64
Current: 19.87

-37.2
20.64
Net-margin (%) 10.91
DGX's Net-margin (%) is ranked higher than
90% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. DGX: 10.91 )
DGX' s 10-Year Net-margin (%) Range
Min: -38.73   Max: 11.88
Current: 10.91

-38.73
11.88
ROE (%) 19.83
DGX's ROE (%) is ranked higher than
92% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. DGX: 19.83 )
DGX' s 10-Year ROE (%) Range
Min: -4.13   Max: 21.63
Current: 19.83

-4.13
21.63
ROA (%) 8.49
DGX's ROA (%) is ranked higher than
87% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. DGX: 8.49 )
DGX' s 10-Year ROA (%) Range
Min: -1.6   Max: 11.74
Current: 8.49

-1.6
11.74
ROC (Joel Greenblatt) (%) 125.52
DGX's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.66 vs. DGX: 125.52 )
DGX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 24.96   Max: 142.93
Current: 125.52

24.96
142.93
Revenue Growth (%) 4.00
DGX's Revenue Growth (%) is ranked higher than
68% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. DGX: 4.00 )
DGX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 15.4
Current: 4

0
15.4
EBITDA Growth (%) 9.40
DGX's EBITDA Growth (%) is ranked higher than
78% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. DGX: 9.40 )
DGX' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 44.5
Current: 9.4

0
44.5
EPS Growth (%) 9.40
DGX's EPS Growth (%) is ranked higher than
77% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. DGX: 9.40 )
DGX' s 10-Year EPS Growth (%) Range
Min: 0   Max: 62.3
Current: 9.4

0
62.3
» DGX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DGX Guru Trades in Q4 2013

Steven Cohen 63,695 sh (+1380.59%)
Paul Tudor Jones 26,689 sh (+641.36%)
Joel Greenblatt 279,188 sh (+533.63%)
John Rogers 268,053 sh (+447.73%)
Richard Pzena 1,215,050 sh (+81.17%)
Jeff Auxier 80,350 sh (+31.61%)
Brian Rogers 2,750,000 sh (+25%)
Robert Olstein 93,000 sh (+12.05%)
Murray Stahl 7,400 sh (+11.28%)
Chuck Royce 171,100 sh (+9.79%)
Diamond Hill Capital 2,049,646 sh (+4.86%)
Bernard Horn 42,933 sh (unchged)
Jim Simons Sold Out
HOTCHKIS & WILEY 2,017,600 sh (-3.74%)
David Dreman 29,218 sh (-28.19%)
Alan Fournier 237,778 sh (-44.14%)
Jeremy Grantham 377,008 sh (-74.28%)
» More
Q1 2014

DGX Guru Trades in Q1 2014

Larry Robbins 1,951,300 sh (New)
Manning & Napier Advisors, Inc 191,490 sh (New)
Ray Dalio 78,977 sh (New)
Louis Moore Bacon 7,800 sh (New)
Chris Davis 102,337 sh (New)
Paul Tudor Jones 406,067 sh (+1421.48%)
Steven Cohen 110,044 sh (+72.77%)
David Dreman 48,748 sh (+66.84%)
Bernard Horn 61,733 sh (+43.79%)
HOTCHKIS & WILEY 2,495,500 sh (+23.69%)
Chuck Royce 188,600 sh (+10.23%)
John Rogers 295,159 sh (+10.11%)
Brian Rogers 3,000,000 sh (+9.09%)
Robert Olstein 100,000 sh (+7.53%)
Murray Stahl 7,850 sh (+6.08%)
Jeff Auxier 80,350 sh (unchged)
Alan Fournier Sold Out
Richard Pzena 972,200 sh (-19.99%)
Joel Greenblatt 76,412 sh (-72.63%)
Jeremy Grantham 91,500 sh (-75.73%)
Diamond Hill Capital 253,642 sh (-87.63%)
» More
Q2 2014

DGX Guru Trades in Q2 2014

Scott Black 220 sh (New)
Chris Davis 4,672,681 sh (+4465.97%)
Louis Moore Bacon 14,460 sh (+85.38%)
John Rogers 352,928 sh (+19.57%)
HOTCHKIS & WILEY 2,523,400 sh (+1.12%)
Manning & Napier Advisors, Inc 193,424 sh (+1.01%)
Bernard Horn 61,733 sh (unchged)
Brian Rogers 3,000,000 sh (unchged)
Steven Cohen 155,400 sh (unchged)
Larry Robbins Sold Out
Jeremy Grantham Sold Out
Chuck Royce 187,500 sh (-0.58%)
Jeff Auxier 79,000 sh (-1.68%)
Murray Stahl 7,050 sh (-10.19%)
Robert Olstein 82,000 sh (-18%)
David Dreman 35,982 sh (-26.19%)
Diamond Hill Capital 124,800 sh (-50.8%)
Richard Pzena 431,100 sh (-55.66%)
Ray Dalio 13,545 sh (-82.85%)
Joel Greenblatt 4,384 sh (-94.26%)
Paul Tudor Jones 8,400 sh (-97.93%)
» More
Q3 2014

DGX Guru Trades in Q3 2014

Brian Rogers 3,000,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Chris Davis 2014-06-30 Add 4465.97%0.8%$55.5 - $61.75 $ 59.652%4672681
Richard Pzena 2014-06-30 Reduce -55.66%0.18%$55.5 - $61.75 $ 59.652%431100
Robert Olstein 2014-06-30 Reduce -18%0.14%$55.5 - $61.75 $ 59.652%82000
Joel Greenblatt 2014-06-30 Reduce -94.26%0.06%$55.5 - $61.75 $ 59.652%4384
David Dreman 2014-06-30 Reduce -26.19%0.06%$55.5 - $61.75 $ 59.652%35982
Ray Dalio 2014-06-30 Reduce -82.85%0.03%$55.5 - $61.75 $ 59.652%13545
Scott Black 2014-06-30 New Buy$55.5 - $61.75 $ 59.652%220
Joel Greenblatt 2014-03-31 Reduce -72.63%0.26%$50.8 - $57.99 $ 59.6511%76412
HOTCHKIS & WILEY 2014-03-31 Add 23.69%0.1%$50.8 - $57.99 $ 59.6511%2495500
David Dreman 2014-03-31 Add 66.84%0.09%$50.8 - $57.99 $ 59.6511%48748
Ray Dalio 2014-03-31 New Buy0.04%$50.8 - $57.99 $ 59.6511%78977
Chris Davis 2014-03-31 New Buy0.02%$50.8 - $57.99 $ 59.6511%102337
Joel Greenblatt 2013-12-31 Add 533.63%0.3%$52.79 - $63.7 $ 59.650%279188
Richard Pzena 2013-12-31 Add 81.17%0.17%$52.79 - $63.7 $ 59.650%1215050
John Rogers 2013-12-31 Add 447.73%0.15%$52.79 - $63.7 $ 59.650%268053
Brian Rogers 2013-12-31 Add 25%0.11%$52.79 - $63.7 $ 59.650%2750000
David Dreman 2013-12-31 Reduce -28.19%0.06%$52.79 - $63.7 $ 59.650%29218
HOTCHKIS & WILEY 2013-09-30 Add 61.93%0.23%$57.96 - $62.48 $ 59.650%2095900
John Rogers 2013-09-30 Add 557.34%0.04%$57.96 - $62.48 $ 59.650%48939
Joel Greenblatt 2013-09-30 Add 41.25%0.03%$57.96 - $62.48 $ 59.650%44062
Ray Dalio 2013-09-30 Sold Out $57.96 - $62.48 $ 59.650%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Quest Diagnostics Inc

Bernard Horn Comments on Quest Diagnostics - Aug 07, 2014

The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations.

From Bernard Horn (Trades, Portfolio)’s Polaris Global Value Fund Second Quarter 2014 Shareholder Letter.

Check out Bernard Horn latest stock trades

Diamond Hill Capital Comments on Quest Diagnostics - Mar 05, 2014

Medical diagnostic testing provider Quest Diagnostics, Inc. (DGX) underperformed due to weakness in both volumes and pricing.



From Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2013 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

DGX: A Healthy Diagnosis
How much are you paying for the revenue of companies in your portfolio? The less you pay per dollar of revenue, the better. Why? Because revenue translates into earning power, and as we know, when earnings grow, they pull up stock prices. As with almost any asset, buying for less is best if it's an investment of some kind. Read more...
The Top Five Guru-Held Mid-Cap Stocks of Q2
Using the GuruFocus Aggregated Portfolio Screener you can filter results to see what companies maintain the highest amount of guru ownership. By using this screener, we filtered down to see mid-cap companies which are held by the most gurus. The following five mid-capped companies are held by the largest number of gurus during the past quarter. Read more...
Bernard Horn Comments on Quest Diagnostics
The world’s largest provider of medical testing services, Quest Diagnostics (DGX), saw its share price rise after announcing its partnership with Memorial Sloan Kettering in New York to screen patients’ cancer genes for genetic mutations. Read more...
Medical Diagnostic Labs Facing Medicare Headwinds
Currently medical diagnostic lab stocks are trading at near historical lows for price-to-sales (P/S). At first sight these companies might look like bargains, but lower p/s ratios might be the new normal for these companies. I have taken a closer look at Lab Corp of America (LH), Quest Diagnostics (DGX), and Bio-Reference Labs (BRLI). Read more...
Diamond Hill Capital Comments on Quest Diagnostics
Medical diagnostic testing provider Quest Diagnostics, Inc. (DGX) underperformed due to weakness in both volumes and pricing. Read more...
Numerous Gurus Hold IDCC, DGX, PTR at 10-Year Low P/B
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, InterDigital Inc. (IDCC), Quest Diagnostics Inc. (DGX) and PetroChina Co. Ltd. (PTR) are held by numerous gurus and are traded at or near their 10-year low. Furthermore, insiders are selling IDCC and DGX. Read more...
DGX, STO, LSE:DOM - Gurus Hold Stocks Traded at 10-Year Low P/B
According to the GuruFocus Value Screen that shows value strategies of stocks traded at historical low P/B ratios, Quest Diagnostics Inc. (DGX), Statoil ASA (STO) and Domino’s Pizza Group PLC (LSE:DOM) are stocks owned by gurus and traded at or near their 10-year historical low P/B ratios. Check out these company updates and trade highlights as of the third quarter of 2013. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 11.30
DGX's P/E(ttm) is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 11.30 )
DGX' s 10-Year P/E(ttm) Range
Min: 9.13   Max: 31.21
Current: 11.3

9.13
31.21
P/B 2.10
DGX's P/B is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. DGX: 2.10 )
DGX' s 10-Year P/B Range
Min: 1.87   Max: 4.43
Current: 2.1

1.87
4.43
P/S 1.20
DGX's P/S is ranked higher than
86% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.86 vs. DGX: 1.20 )
DGX' s 10-Year P/S Range
Min: 1.03   Max: 2.24
Current: 1.2

1.03
2.24
PFCF 17.00
DGX's PFCF is ranked higher than
94% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 17.00 )
DGX' s 10-Year PFCF Range
Min: 8.22   Max: 21.5
Current: 17

8.22
21.5
EV-to-EBIT 8.64
DGX's EV-to-EBIT is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 8.64 )
DGX' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 14.2
Current: 8.64

7.2
14.2
PEG 1.65
DGX's PEG is ranked higher than
94% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 1.65 )
DGX' s 10-Year PEG Range
Min: 0.53   Max: 4.42
Current: 1.65

0.53
4.42
Shiller P/E 14.70
DGX's Shiller P/E is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 14.70 )
DGX' s 10-Year Shiller P/E Range
Min: 12.83   Max: 47.75
Current: 14.7

12.83
47.75
Current Ratio 1.20
DGX's Current Ratio is ranked higher than
52% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. DGX: 1.20 )
DGX' s 10-Year Current Ratio Range
Min: 0.74   Max: 2.15
Current: 1.2

0.74
2.15
Quick Ratio 1.11
DGX's Quick Ratio is ranked higher than
52% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. DGX: 1.11 )
DGX' s 10-Year Quick Ratio Range
Min: 0.7   Max: 2.03
Current: 1.11

0.7
2.03

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.20
DGX's Dividend Yield is ranked higher than
76% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.29 vs. DGX: 2.20 )
DGX' s 10-Year Dividend Yield Range
Min: 0.35   Max: 2.36
Current: 2.2

0.35
2.36
Dividend Payout 0.24
DGX's Dividend Payout is ranked higher than
91% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.24 )
DGX' s 10-Year Dividend Payout Range
Min: 0.09   Max: 0.86
Current: 0.24

0.09
0.86
Dividend growth (3y) 55.40
DGX's Dividend growth (3y) is ranked higher than
94% of the 35 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.90 vs. DGX: 55.40 )
DGX' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 55.4
Current: 55.4

0
55.4
Yield on cost (5-Year) 9.33
DGX's Yield on cost (5-Year) is ranked higher than
87% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DGX: 9.33 )
DGX' s 10-Year Yield on cost (5-Year) Range
Min: 1.48   Max: 10.01
Current: 9.33

1.48
10.01
Share Buyback Rate 4.80
DGX's Share Buyback Rate is ranked higher than
97% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. DGX: 4.80 )
DGX' s 10-Year Share Buyback Rate Range
Min: 0   Max: -17.7
Current: 4.8

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.80
DGX's Price/DCF (Projected) is ranked higher than
98% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 0.80 )
DGX' s 10-Year Price/DCF (Projected) Range
Min: 0.65   Max: 4.46
Current: 0.8

0.65
4.46
Price/Median PS Value 0.90
DGX's Price/Median PS Value is ranked higher than
84% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.27 vs. DGX: 0.90 )
DGX' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 1.61
Current: 0.9

0.23
1.61
Price/Peter Lynch Fair Value 1.50
DGX's Price/Peter Lynch Fair Value is ranked higher than
94% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 1.50 )
DGX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.62   Max: 3.65
Current: 1.5

0.62
3.65
Earnings Yield (Greenblatt) 11.40
DGX's Earnings Yield (Greenblatt) is ranked higher than
89% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. DGX: 11.40 )
DGX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 7   Max: 13.8
Current: 11.4

7
13.8
Forward Rate of Return (Yacktman) 14.11
DGX's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. DGX: 14.11 )
DGX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 11.7   Max: 33.1
Current: 14.11

11.7
33.1

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, LIFE, ENZ, IDXX » details
Traded in other countries:QDI.Germany
Quest Diagnostics Inc was incorporated in Delaware in 1990. The Company and its subsidiaries are the providers of diagnostic testing, information and services, providing insights that enable patients and physicians to make better healthcare decisions. The Company offers U.S. patients and physicians the broadest access to diagnostic testing services through its nationwide network of laboratories and Company-owned patient service centers. It provides interpretive consultation through the largest medical and scientific staff in the industry, including hundreds of M.D.s and Ph.D.s, primarily located in the United States. The Company is a provider of clinical testing, including gene-based and esoteric testing and anatomic pathology services, and provider of risk assessment services for the life insurance industry. The Company is also a provider of testing for clinical trials and testing for drugs of abuse. The Company's diagnostics products business manufactures and markets diagnostic test kits and specialized point-of-care testing. The Company empowers healthcare organizations and clinicians with state-of-the-art information technology solutions that can improve patient care and medical practice. It is the commercial clinical testing company. It offers customers the access to the extensive test menu of clinical and anatomic pathology tests in the United States. It performs routine testing through its network of major laboratories and rapid response laboratories. It is a provider of cancer diagnostics, including anatomic pathology services, in the United States. Gene-based and other esoteric tests increasingly are ordered by physicians to assist them in the diagnostic process, to establish a prognosis and to choose or monitor a therapeutic regimen. Esoteric tests include procedures in the areas of molecular diagnostics, protein chemistry, cellular immunology and advanced microbiology. The Company is an innovator in the clinical testing industry, with capabilities ranging from early discovery to validation of clinical tests. It develops tests at its laboratories, such as Quest Diagnostics Nichols Institute; it also develops innovative techniques in anatomic pathology. Its industry remains fragmented and highly competitive. The Company mainly competes with three types of clinical testing providers: hospital-affiliated laboratories, other commercial clinical laboratories and physician-office laboratories. The Company's businesses are subject to or impacted by extensive and frequently changing laws and regulations in the United States at both the federal and state levels and the other jurisdictions in which it conduct business.
» More Articles for DGX

Headlines

Articles On GuruFocus.com
DGX: A Healthy Diagnosis Oct 08 2014 
The Top Five Guru-Held Mid-Cap Stocks of Q2 Sep 04 2014 
LabCorp: A Leading Independent Diagnostic Laboratory Aug 22 2014 
Bernard Horn Comments on Quest Diagnostics Aug 07 2014 
Top Five Guru-Owned Mid Cap Stocks Jun 18 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S May 28 2014 
Morning Coffee: Widely Held Guru Stocks Near Historic Low P/S May 13 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B May 05 2014 
Morning Coffee: Widely Held Guru Stocks Trading Near Historical Low P/S Apr 29 2014 
Morning Coffee: Widely Held Guru Stocks Near Historical Low P/B Apr 28 2014 

More From Other Websites
Mayo Clinic files lawsuit against former executive Oct 16 2014
Quest Diagnostics To Release Third Quarter 2014 Financial Results On October 23 Oct 07 2014
Quest Diagnostics To Host Investor Day On November 5, 2014 Oct 01 2014
Quest Diagnostics Names Mayo Clinic Executive Franklin R. Cockerill, M.D., Vice President and Chief... Oct 01 2014
Practice Fusion to Provide Access to Electronic Laboratory Test Ordering and Reporting with Quest... Sep 25 2014
[video] Getting Your Medical Tests Online: Pros and Cons Sep 15 2014
Quest Diagnostics Marks 10 Years on the Dow Jones Sustainability Index Sep 12 2014
Workforce Drug Test Positivity Rate Increases for the First Time in 10 Years, Driven by Marijuana... Sep 11 2014
DGX, HUM And AET, 3 Health Services Stocks Pushing The Industry Lower Sep 10 2014
More People Testing Positive for Chikungunya Virus in the U.S., Finds Study at ICAAC 2014 Sep 08 2014
Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference Sep 04 2014
Early Look at the Hammerstone Report (Street Rec's Roundup) Sep 03 2014
Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According... Aug 27 2014
Air Methods Navigates To Grow Medical Flight Business Aug 18 2014
Quest Diagnostics Declares Quarterly Cash Dividend Aug 15 2014
Myriad Genetics: Not as Bad as It Looks? Aug 13 2014
Myriad Genetics Guidance Disappoints, Q4 Edges Views Aug 12 2014
Myriad Genetics' Earnings Face 'Angelina Jolie' Comps Aug 11 2014
QUEST DIAGNOSTICS INC Financials Aug 08 2014
Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation (CTSO), Interviews with The... Aug 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK